Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NK
Nkarta, Inc. Common Stock
NKTX
Mkt Cap
$130.0M
Volume
1.69M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NK
NKTX
NK
Nkarta, Inc. Common Stock
NKTX
News
·
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Mkt Cap
$128.9M
Volume
1.69M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta, Inc. announced selection for three scientific presentations at ACR Convergence 2026 in November, including two oral presentations on NKX019's safety profile and clinical activity in idiopathic inflammatory myopathy, and one poster presentation on systemic sclerosis. The company is advancing NKX019, an allogeneic CAR-NK cell therapy targeting CD19 in B-cell-mediated autoimmune diseases, with enrollment ongoing in the Ntrust Phase 1/2 clinical trials across multiple indications.
GlobeNewswire Inc. · Sep 8, 2026
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The company reported ongoing enrollment in clinical trials at 4 billion cell dose levels and secured FDA agreement for outpatient dosing of NKX019, enabling treatment in community rheumatology centers and expanding patient access.
GlobeNewswire Inc. · Jun 26, 2026
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.
GlobeNewswire Inc. · Apr 6, 2026
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered NK cell therapies for autoimmune diseases, announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 in Boston, and the Leerink Global Healthcare Conference on March 10, 2026 in Miami. Both presentations will be available via webcast.
GlobeNewswire Inc. · Feb 27, 2026
Nkarta to Participate in an April Investor Conference
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.
GlobeNewswire Inc. · Apr 1, 2025
Nkarta to Participate in an Upcoming Investor Conference
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024.
GlobeNewswire Inc. · Nov 26, 2024
Nkarta to Participate in Upcoming Investor Conference
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
GlobeNewswire Inc. · Sep 3, 2024
Why Nkarta Stock Is Soaring Today
Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.
The Motley Fool · Aug 14, 2024
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President - GlobeNewswire
Nkarta, a biopharmaceutical company, announced changes to its leadership team, including the appointment of Nadir Mahmood as President and the promotion of David R. Shook to Chief Medical Officer and Head of Research & Development.
GlobeNewswire Inc. · Jul 16, 2024
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
GlobeNewswire Inc. · Jun 27, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NK
NKTX
Nkarta, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
NKTX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NKTX yet.
Related Tickers
Earnings